1. Home
  2. TROO vs SKYE Comparison

TROO vs SKYE Comparison

Compare TROO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TROO
  • SKYE
  • Stock Information
  • Founded
  • TROO 2005
  • SKYE 2012
  • Country
  • TROO Hong Kong
  • SKYE United States
  • Employees
  • TROO N/A
  • SKYE N/A
  • Industry
  • TROO Radio And Television Broadcasting And Communications Equipment
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • TROO Technology
  • SKYE Health Care
  • Exchange
  • TROO Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • TROO 299.7M
  • SKYE 294.2M
  • IPO Year
  • TROO N/A
  • SKYE N/A
  • Fundamental
  • Price
  • TROO $3.27
  • SKYE $6.44
  • Analyst Decision
  • TROO
  • SKYE Strong Buy
  • Analyst Count
  • TROO 0
  • SKYE 4
  • Target Price
  • TROO N/A
  • SKYE $19.25
  • AVG Volume (30 Days)
  • TROO 92.0K
  • SKYE 414.1K
  • Earning Date
  • TROO 07-16-2024
  • SKYE 01-01-0001
  • Dividend Yield
  • TROO N/A
  • SKYE N/A
  • EPS Growth
  • TROO N/A
  • SKYE N/A
  • EPS
  • TROO N/A
  • SKYE N/A
  • Revenue
  • TROO $3,569,000.00
  • SKYE N/A
  • Revenue This Year
  • TROO N/A
  • SKYE N/A
  • Revenue Next Year
  • TROO N/A
  • SKYE N/A
  • P/E Ratio
  • TROO N/A
  • SKYE N/A
  • Revenue Growth
  • TROO N/A
  • SKYE N/A
  • 52 Week Low
  • TROO $0.73
  • SKYE $1.44
  • 52 Week High
  • TROO $4.79
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • TROO 71.04
  • SKYE 36.20
  • Support Level
  • TROO $2.06
  • SKYE $5.48
  • Resistance Level
  • TROO $3.46
  • SKYE $6.93
  • Average True Range (ATR)
  • TROO 0.50
  • SKYE 1.03
  • MACD
  • TROO 0.06
  • SKYE -0.03
  • Stochastic Oscillator
  • TROO 90.26
  • SKYE 37.30

About TROO TROOPS Inc.

TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: